PMID- 1330596
OWN - NLM
STAT- MEDLINE
DCOM- 19921127
LR  - 20190623
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 218
IP  - 2-3
DP  - 1992 Aug 6
TI  - Arachidonic acid release and platelet-activating factor formation by 
      staurosporine in human neutrophils challenged with n-formyl peptide.
PG  - 251-8
AB  - Staurosporine, a putative protein kinase C (PKC) inhibitor, increased the release 
      of [14C]arachidonic acid dose dependently between 100 nM and 1000 nM in human 
      neutrophils challenged with 100 nM N-formyl-methionine-leucine-phenylalanine 
      (FMLP). Staurosporine also increased the formation of leukotriene B4 (LTB4) and 
      platelet-activating factor (PAF) in a dose-dependent manner. In addition, 
      exogenously added lyso-PAF further augmented [3H]PAF formation in 
      staurosporine-pretreated human neutrophils stimulated by FMLP, thus suggesting an 
      activation of acetyl-CoA: lyso-PAF acetyltransferase by staurosporine. The 
      potentiation of [14C]arachidonic acid release and [3H]PAF formation by 
      staurosporine was further enhanced in the presence of 100 nM phorbol 12-myristate 
      13-acetate (PMA), which pinpoints a mechanism other than the modulation of PKC in 
      this process, inasmuch as staurosporine antagonizes PMA-induced O2- production 
      and [3H]PAF formation. Additional studies with other putative PKC inhibitors also 
      revealed the potentiating effects of 1-(5-isoquinolinsulfonyl)-2-methylpiperazine 
      (H-7, 20 microM) and sphingosine (2.5 microM) on FMLP-induced [14C]arachidonic 
      acid release and [3H]PAF formation. We therefore conjecture that 
      staurosporine-sensitive protein kinases including PKC are not involved in the 
      activation of phospholipase A2 and acetyl-CoA:lyso-PAF acetyltransferase.
FAU - Muller, S
AU  - Muller S
AD  - Department of Gynecology, Universitatsklinikum Steglitz, Free University Berlin, 
      Germany.
FAU - Nigam, S
AU  - Nigam S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Alkaloids)
RN  - 0 (Platelet Activating Factor)
RN  - 1HGW4DR56D (Leukotriene B4)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - H88EPA0A3N (Staurosporine)
SB  - IM
MH  - Alkaloids/*pharmacology
MH  - Arachidonic Acid/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - In Vitro Techniques
MH  - Leukotriene B4/biosynthesis
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/*drug effects/metabolism
MH  - Phospholipases A/metabolism
MH  - Phospholipases A2
MH  - Platelet Activating Factor/*biosynthesis
MH  - Protein Kinase C/*antagonists & inhibitors
MH  - Staurosporine
EDAT- 1992/08/06 00:00
MHDA- 1992/08/06 00:01
CRDT- 1992/08/06 00:00
PHST- 1992/08/06 00:00 [pubmed]
PHST- 1992/08/06 00:01 [medline]
PHST- 1992/08/06 00:00 [entrez]
AID - 0014-2999(92)90176-5 [pii]
AID - 10.1016/0014-2999(92)90176-5 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1992 Aug 6;218(2-3):251-8. doi: 10.1016/0014-2999(92)90176-5.